A Cross-Cultural Assessment of the Motivations of Healthy Participants in Phase I Research
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01485250|
Recruitment Status : Completed
First Posted : December 5, 2011
Last Update Posted : January 14, 2019
- Individuals often participate in clinical trials to seek new therapies and free medical treatments for their illnesses or chronic conditions. However, less is known about the motivations of the healthy individuals who volunteer for research studies.
- Although many healthy volunteers participate in clinical trials for financial compensation, the particular risks involved in testing drugs that have not been tried in human clinical trials pose potential dangers for healthy volunteers in Phase I studies. More research is needed to understand the motivations of volunteers who participate in Phase I clinical trials.
- To evaluate the primary and secondary motivations of healthy participants in research studies.
- Individuals at least 18 years of age who are healthy volunteers in selected Pfizer Phase I clinical trials.
- Individuals who express interest in participating in specific Pfizer Phase I drug studies will be asked to complete a short questionnaire after completing the standard consent session for the study.
- Those who enroll in the trial will be asked to complete a second questionnaire prior to discharge from the study.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||1278 participants|
|Official Title:||A Cross-Cultural Assessment of the Motivations of Healthy Participants in Phase I Research|
|Study Start Date :||February 19, 2010|
|Study Completion Date :||August 8, 2018|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01485250
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Christine Grady, M.D.||National Institutes of Health Clinical Center (CC)|